

**Amendments to the Claims:**

This listing of the claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-24. (Canceled)

25. (Currently amended) A method of reducing kidney fibrosis in a mammal comprising administering to a mammal having a fibroproliferative disorder of kidney a composition comprising ~~an~~ a humanized monoclonal antibody or a human monoclonal antibody that specifically binds to an epitope of a protein as shown in SEQ ID NO:2 from amino acid residue 19 to amino acid residue 370, in combination with a pharmaceutically acceptable delivery vehicle, wherein said antibody is an antagonist of said protein, in an amount sufficient to reduce kidney fibrosis in the mammal, wherein the fibroproliferative disorder is characterized by mesangial cell proliferation.

26. (Canceled)

27. (Currently amended) The method of claim 25 wherein the antibody is a humanized monoclonal antibody.

28. (Currently amended) The method of claim 25 wherein the fibroproliferative disorder of kidney is ~~glomerulonephritis,~~ membranoproliferative glomerulonephritis, diffuse proliferative glomerulonephritis, diabetic nephropathy, or lupus nephritis.

29. (Canceled)

30. (Previously presented) The method of claim 25 wherein the antibody binds to an epitope of a protein as shown in SEQ ID NO:2 from amino acid residue 258 to amino acid residue 370.

31. (Currently amended) The method of claim 30 wherein the fibroproliferative disorder of kidney is ~~glomerulonephritis,~~ membranoproliferative

glomerulonephritis, diffuse proliferative glomerulonephritis, diabetic nephropathy, or lupus nephritis.

32. (Canceled)

33. (New) The method of claim 25 wherein the fibroproliferative disorder of kidney is further characterized by extracellular matrix accumulation.